The Readout Damian Garde The saga of a ‘criminal’ short report, Moderna’s valuation, & UniQure’s patents
The Readout Damian Garde Pfizer’s 95% vaccine efficacy, disappointment in ALS, & FDA promises of transparency
The Readout Damian Garde FDA conspiracy theories, closing the Covid vaccine gap, & how to value a Vant
The Readout Damian Garde Aduhelm’s other profiteers, the latest SPAC merger, & BIO’s CEO on FDA rumors
The Readout Meghana Keshavan Aduhelm’s impact on Medicare, a new CRISPR therapy, & a Warp Speed retirement
The Readout Damian Garde Inside the FDA’s Aduhelm decision, GSK’s pitch for the future, & a biopharma gadfly joins the industry
The Readout Damian Garde Calif. law failed to increase generic drug use, EU loses bid against AstraZeneca, & a medical journal goes to battle against a journal
The Readout Damian Garde Biotech CEO suspended over altered data probe, Biden’s $3.2B plan for Covid pills, & the booster shot debate
The Readout Damian Garde CureVac’s Covid-19 disappointment, a NICE for U.S., & Biogen’s other Alzheimer’s treatment
The Readout Damian Garde How the FDA thought about Aduhelm, SPACs explained, & June’s biotech binaries
The Readout Damian Garde FDA’s momentous Biogen decision, a new day in Alzheimer’s, & Shkreli’s reprieve
The Readout Damian Garde and Meghana Keshavan Biogen’s big day, an EU vaccine plan, & an NK trial win
The Readout Damian Garde Biotech’s buyout fizzle, a parent-sponsored clinical trial, & CureVac’s curious tweet
The Readout Meghana Keshavan Pfizer’s profitable slowdown, Lilly under scrutiny, & reversing a grandfathering rule
The Readout Damian Garde CureVac’s any-day-now data, more FDA conservatism, & a lawsuit about coupons
The Readout Damian Garde A middle path for aducanumab, losing money on the biotech boom, & the importance of subject lines
The Readout Damian Garde The NASH gold rush is waning, Zolgensma turns 2, & the dawn of federal biotech bonds
The Readout Damian Garde and Meghana Keshavan Biotech meme stocks, price competition in immunotherapy, & a heart-shaped mass of stem cells
The Readout Damian Garde The latest in CAR-T, Iovance’s rough 24 hours, & a copyright fight in gene therapy
The Readout Damian Garde AbbVie’s failed pop quiz, Sarepta’s incremental victory, & pharma’s cyber risk